ES2119411T5 - Combinaciones de proteinas y anticoagulantes tromboliticamente activos, y usos de los mismos. - Google Patents

Combinaciones de proteinas y anticoagulantes tromboliticamente activos, y usos de los mismos.

Info

Publication number
ES2119411T5
ES2119411T5 ES95912261T ES95912261T ES2119411T5 ES 2119411 T5 ES2119411 T5 ES 2119411T5 ES 95912261 T ES95912261 T ES 95912261T ES 95912261 T ES95912261 T ES 95912261T ES 2119411 T5 ES2119411 T5 ES 2119411T5
Authority
ES
Spain
Prior art keywords
anticoagulants
active
trombolitically
proteins
combinations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95912261T
Other languages
English (en)
Other versions
ES2119411T3 (es
Inventor
Ulrich Martin
Stephan Fischer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22811809&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2119411(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Application granted granted Critical
Publication of ES2119411T3 publication Critical patent/ES2119411T3/es
Publication of ES2119411T5 publication Critical patent/ES2119411T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A COMPOSICIONES Y METODOS TERAPEUTICOS TROMBOLITICAMENTE EFECTIVAS. LAS PROTEINAS ACTIVAS TROMBOLITICAMENTE SE COMBINAN CON ANTICOAGULANTES, SIEMPRE QUE EL ANTICOAGULANTE NO SEA LA HEPARINA. EL ANTICOAGULANTE SE ADMINISTRA EN FORMA DE BOLO INTRAVENOSO MIENTRAS QUE LA PROTEINA TROMBOLITICAMENTE ACTIVA PUEDE ADMINISTRARSE VIA BOLO INTRAVENOSO O MEDIANTE INFUSION INTRAVENOSA.
ES95912261T 1994-03-25 1995-03-22 Combinaciones de proteinas y anticoagulantes tromboliticamente activos, y usos de los mismos. Expired - Lifetime ES2119411T5 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/217,618 US5510330A (en) 1994-03-25 1994-03-25 Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.

Publications (2)

Publication Number Publication Date
ES2119411T3 ES2119411T3 (es) 1998-10-01
ES2119411T5 true ES2119411T5 (es) 2002-08-01

Family

ID=22811809

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95912261T Expired - Lifetime ES2119411T5 (es) 1994-03-25 1995-03-22 Combinaciones de proteinas y anticoagulantes tromboliticamente activos, y usos de los mismos.

Country Status (21)

Country Link
US (1) US5510330A (es)
EP (2) EP0751785B2 (es)
JP (1) JPH09510439A (es)
KR (1) KR100366982B1 (es)
CN (1) CN1090029C (es)
AT (1) ATE167631T1 (es)
AU (1) AU702470B2 (es)
BR (1) BR9507189A (es)
CA (1) CA2186390A1 (es)
CZ (1) CZ279596A3 (es)
DE (1) DE69503120T3 (es)
DK (1) DK0751785T4 (es)
ES (1) ES2119411T5 (es)
FI (1) FI120182B (es)
MX (1) MX9603925A (es)
NO (1) NO316584B1 (es)
NZ (1) NZ282417A (es)
PL (1) PL182165B1 (es)
RU (1) RU2166326C2 (es)
UA (1) UA41398C2 (es)
WO (1) WO1995026202A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
US7550005B2 (en) * 1995-06-07 2009-06-23 Cook Incorporated Coated implantable medical device
US20070203520A1 (en) * 1995-06-07 2007-08-30 Dennis Griffin Endovascular filter
US7896914B2 (en) * 1995-06-07 2011-03-01 Cook Incorporated Coated implantable medical device
US7846202B2 (en) 1995-06-07 2010-12-07 Cook Incorporated Coated implantable medical device
US7867275B2 (en) * 1995-06-07 2011-01-11 Cook Incorporated Coated implantable medical device method
US6774278B1 (en) * 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US5840733A (en) * 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
US6010911A (en) * 1997-04-30 2000-01-04 Medtronic, Inc. Apparatus for performing a heparin-independent high sensitivity platelet function evaluation technique
US6750201B1 (en) * 1997-10-17 2004-06-15 The Trustees Of The University Of Pennsylvania Compositions and methods for promoting internalization and degradation of urokinase-type plasminogen activator
US6517814B2 (en) 2001-01-09 2003-02-11 Bristol-Myers Squibb Pharma Company Macrocyclic chelants useful for metallopharmaceuticals
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
FI20020197A0 (fi) * 2002-02-01 2002-02-01 Orion Corp Yhdistelmä akuutin myokardiilisen infarktin hoitoon
US7084118B2 (en) * 2002-02-22 2006-08-01 Genentech, Inc. Combination treatment with t-PA variant and low molecular weight heparin
EP2324866B1 (en) * 2002-07-12 2014-06-18 Cook Medical Technologies LLC Angioplasty balloons drug-coated in an expanded condition
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
ES2375064T3 (es) * 2004-05-17 2012-02-24 Medtronic, Inc. Sistema de determinación de heparina en el lugar de atención al paciente.
US20060222640A1 (en) * 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
TWI482628B (zh) * 2007-10-18 2015-05-01 Lundbeck & Co As H 新穎之血栓溶解病患次群
CN101952309A (zh) * 2007-12-21 2011-01-19 Ifxa有限公司 蛋白酶抑制剂
CA2966332C (en) 2014-11-03 2024-04-16 Thrombolytic Science, Llc Methods and compositions for safe and effective thrombolysis
KR101721068B1 (ko) * 2015-01-30 2017-03-29 고려대학교 산학협력단 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
RU2622006C2 (ru) * 2015-06-15 2017-06-08 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Казанский (Приволжский) федеральный университет" (ФГАОУВПО КФУ) Применение рекомбинантного штамма bacillus subtilis eo-11 вкпм в-11978 в качестве продуцента субтилизиноподобной протеиназы, вещества с тромболитическими и антикоагулянтными свойствами
CN105396127A (zh) * 2015-11-13 2016-03-16 中国人民解放军第四军医大学 一种用于急性心肌梗死的冠状动脉溶栓剂
WO2018232305A1 (en) * 2017-06-16 2018-12-20 Thrombolytic Science, Llc Methods and compositions for thrombolysis
CN117534731A (zh) * 2021-09-24 2024-02-09 江西康之康中药科技有限公司 一种抗凝血肽及其在抗凝血产品上的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8508717D0 (en) * 1985-04-03 1985-05-09 Beecham Group Plc Composition
DK43387A (da) † 1986-01-29 1987-07-30 Beecham Group Plc Fibrinolytisk enzym
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
DE3804600A1 (de) * 1988-02-13 1989-08-24 Basf Ag Mischung aus einer thrombolytisch wirkenden und einer antithrombotischen substanz
GB8822147D0 (en) * 1988-09-21 1988-10-26 Ciba Geigy Ag Pharmaceutically active combination
US5204323B1 (en) * 1988-10-06 1995-07-18 Ciba Geigy Corp Hirudin antidotal compositions and methods
GB8826428D0 (en) * 1988-11-11 1988-12-14 Biopharm Ltd Antithrombin
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
DE3903581A1 (de) * 1989-02-07 1990-08-16 Boehringer Mannheim Gmbh Gewebs-plasminogenaktivator-derivat
EP0482069A1 (en) * 1989-07-20 1992-04-29 Biogen, Inc. Combinations and methods for treating or preventing thrombotic diseases
US5240913A (en) * 1989-08-18 1993-08-31 Biogen, Inc. Inhibitors of thrombin
US5196404B1 (en) * 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
US5049132A (en) * 1990-01-08 1991-09-17 Cordis Corporation Balloon catheter for delivering therapeutic agents
US5189019A (en) * 1990-04-23 1993-02-23 Merck & Co., Inc. Antistasin derived anticoagulant protein
US5242810A (en) * 1990-12-07 1993-09-07 Biogen, Inc. Bifunctional inhibitors of thrombin and platelet activation
US5242688A (en) * 1990-12-24 1993-09-07 Eli Lilly And Company Method of treating thromboembolic disorders by administration of diglycosylated t-pa variants
US5500411A (en) † 1991-04-16 1996-03-19 Boehringer Mannheim Gmbh Method for treating thromboembolic conditions by inhibiting reocclusion via the use of multiple bolus administration of thrombolytically active proteins
AU664469B2 (en) † 1992-06-03 1995-11-16 Genentech Inc. Tissue plasminogen activator glycosylation variants with improved therapeutic properties

Also Published As

Publication number Publication date
EP0751785B1 (en) 1998-06-24
KR100366982B1 (ko) 2003-08-02
UA41398C2 (uk) 2001-09-17
ES2119411T3 (es) 1998-10-01
EP0850648A3 (en) 2004-03-31
NO964007L (no) 1996-11-25
DE69503120T3 (de) 2003-08-14
PL316449A1 (en) 1997-01-20
FI120182B (fi) 2009-07-31
AU702470B2 (en) 1999-02-25
FI963802A (fi) 1996-09-24
EP0850648A2 (en) 1998-07-01
NZ282417A (en) 1998-02-26
CN1144489A (zh) 1997-03-05
DE69503120T2 (de) 1998-11-12
EP0751785B2 (en) 2001-12-19
NO316584B1 (no) 2004-03-01
FI963802A0 (fi) 1996-09-24
US5510330A (en) 1996-04-23
BR9507189A (pt) 1997-09-09
MX9603925A (es) 1997-04-30
WO1995026202A1 (en) 1995-10-05
EP0751785A1 (en) 1997-01-08
AU1951195A (en) 1995-10-17
ATE167631T1 (de) 1998-07-15
RU2166326C2 (ru) 2001-05-10
CA2186390A1 (en) 1995-10-05
JPH09510439A (ja) 1997-10-21
NO964007D0 (no) 1996-09-24
CZ279596A3 (cs) 1998-01-14
PL182165B1 (pl) 2001-11-30
DE69503120D1 (de) 1998-07-30
DK0751785T4 (da) 2002-04-15
CN1090029C (zh) 2002-09-04
DK0751785T3 (da) 1999-04-06

Similar Documents

Publication Publication Date Title
ES2119411T5 (es) Combinaciones de proteinas y anticoagulantes tromboliticamente activos, y usos de los mismos.
FI946004A0 (fi) Lääketieteellisessä toimenpiteessä käytettävä trombiiniverifraktio
IT1216025B (it) Apparecchio atto ad operare, in modo pressoche' istantaneo, la distruzione completa dell'ago di siringhe per iniezione, subito dopo il loro impiego.
BR9913932A (pt) Uso de análogos de glp-1 no tratamento de derrame
FI875533A (fi) Insulinpreparat foer non-parenteral dosering.
FI931097A0 (fi) Laekemedel, deras framstaellning och anvaendning vid bekaempning av smaertor och/eller inflammationen hos maenniskor och djur
IT8709354A0 (it) Siringa per iniezioni,in specie endovenose,realizzata per poteressere usata una sola volta,senza possibilita' di riaspirazione.
DE3876143D1 (de) Wegwerfbare infusionskassette mit pumpenkammer sowie triebwerk dafuer.
ES2075468T3 (es) Vehiculos de suministro de farmacos suspendidos en un portador perfluorado no acuoso.
ES2133326T3 (es) Incremento de la permeabilidad de la barrera hematoencefalica con peptidos permeabilizadores.
ES2112851T3 (es) Separacion por afinidad con membranas microporosas de poliamida activadas.
ES2026126T3 (es) Un sistema para la toma, tratamiento y devolucion de sangre de un paciente.
FR2630328B1 (fr) Derive de l'histamine, sa preparation et son application en therapeutique
FI102293B1 (fi) Ihmisen interleukiini-3:n molekulaarinen kloonaus ja ilmentäminen
ES2119165T3 (es) Nueva actividad de cofactor anticoagulante.
ES2055902T3 (es) Composiciones farmaceuticas de proteinas activadoras del plasminogeno.
FI860018A0 (fi) Laekemedelspreparat med reducerad toxisitet.
ES2055761T3 (es) Procedimiento para la concentracion de los factores de coagulacion de la sangre ii, vii, ix y x.
ATE170076T1 (de) Angiotensin ii-antagonisten zur behandlung von viralen erkrankungen
ITMI920710A0 (it) Siringa di sicurezza con ago retrattile dopo l'uso in modo da evitare il riutilizzo della siringa e la diffusione di malattie contagiose per punture accidentali dell'ago.
DK578887D0 (da) Antihypertensiva
DK226889A (da) Alkoholpeptidderivat samt anvendelse deraf til mindskning af blodkoagulation
ES2062145T3 (es) 1,8-naftiridinas substituidas.
DK0535129T3 (da) Et antikoagulerende præparat
DK0651654T3 (da) Anvendelse af lysozymdimer til fremstilling af et lægemiddel til styrkelse af de naturlige forsvarsmekanismer

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 751785

Country of ref document: ES